Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma.
Méant A, Moussa O, Lebeau B, Gonçalves C, Richard VR, Cai F, Prabhu SA, Langke M, Guettler EM, Su J, Gagnon N, Zahedi RP, Borchers CH, Miller WH Jr, Del Rincón SV, Witcher M. Méant A, et al. Among authors: miller wh jr. J Invest Dermatol. 2024 Oct 1:S0022-202X(24)02160-2. doi: 10.1016/j.jid.2024.07.037. Online ahead of print. J Invest Dermatol. 2024. PMID: 39357785 Free article. No abstract available.
Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis.
Preston SEJ, Dahabieh MS, Flores González RE, Gonçalves C, Richard VR, Leibovitch M, Dakin E, Papadopoulos T, Lopez Naranjo C, McCallum PA, Huang F, Gagnon N, Perrino S, Zahedi RP, Borchers CH, Jones RG, Brodt P, Miller WH Jr, Del Rincón SV. Preston SEJ, et al. Among authors: miller wh jr. Sci Adv. 2024 Sep 13;10(37):eadi7673. doi: 10.1126/sciadv.adi7673. Epub 2024 Sep 13. Sci Adv. 2024. PMID: 39270021 Free PMC article.
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
Cho BC, Braña I, Cirauqui B, Aksoy S, Couture F, Hong RL, Miller WH Jr, Chaves-Conde M, Teixeira M, Leopold L, Munteanu M, Ge JY, Swaby RF, Hughes BGM. Cho BC, et al. Among authors: miller wh jr. BMC Cancer. 2024 Jul 25;23(Suppl 1):1254. doi: 10.1186/s12885-023-11316-0. BMC Cancer. 2024. PMID: 39054467 Free PMC article. Clinical Trial.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: miller wh jr. Invest New Drugs. 2024 Jun;42(3):340-341. doi: 10.1007/s10637-024-01444-0. Invest New Drugs. 2024. PMID: 38767685 Free PMC article. No abstract available.
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymski T, Mazan M, Masiejczyk M, Faber J, Khoury E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem GE, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, Del Rincón SV. Huang F, et al. Among authors: miller wh jr. J Clin Invest. 2024 May 1;134(9):e181575. doi: 10.1172/JCI181575. J Clin Invest. 2024. PMID: 38690739 Free PMC article. No abstract available.
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV. Zhan Y, et al. Among authors: miller wh jr. J Clin Invest. 2024 Apr 15;134(8):e181338. doi: 10.1172/JCI181338. J Clin Invest. 2024. PMID: 38618965 Free PMC article. No abstract available.
Correction: MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.
Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Wichter M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr. Guo Q, et al. Among authors: miller wh jr. Cancer Res. 2024 Apr 15;84(8):1373. doi: 10.1158/0008-5472.CAN-24-0461. Cancer Res. 2024. PMID: 38616659 No abstract available.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Among authors: miller wh jr. Invest New Drugs. 2024 Feb;42(1):145-159. doi: 10.1007/s10637-023-01410-2. Epub 2024 Feb 7. Invest New Drugs. 2024. PMID: 38324085 Free PMC article. Clinical Trial.
312 results